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OBJECTIVE—To investigate the effect of exogenous as well as
endogenous glucagon-like peptide 1 (GLP-1) on postprandial
glucose excursions and to characterize the secretion of incretin
hormones in type 1 diabetic patients with and without residual
b-cell function.
RESEARCH DESIGN AND METHODS—Eight type 1 diabetic
patients with (T1D+), eight without (T1D2) residual b-cell func-
tion, and eight healthy matched control subjects were studied
during a mixed meal with concomitant infusion of GLP-1 (1.2
pmol/kg/min), saline, or exendin 9-39 (300 pmol/kg/min). Before
the meal, half dose of usual fast-acting insulin was injected.
Plasma glucose (PG), glucagon, C-peptide, total GLP-1, intact
glucose-dependent insulinotropic polypeptide (GIP), free fatty
acids, triglycerides, and gastric emptying rate (GE) by plasma
acetaminophen were measured.
RESULTS—Incretin responses did not differ between patients
and control subjects. Infusion of GLP-1 decreased peak PG by
45% in both groups of type 1 diabetic patients. In T1D+ patients,
postprandial PG decreased below fasting levels and was in-
distinguishable from control subjects infused with saline. In
T1D2 patients, postprandial PG remained at fasting levels.
GLP-1 infusion reduced GE and glucagon levels in all groups
and increased fasting C-peptide in T1D+ patients and control
subjects. Blocking endogenous GLP-1 receptor action increased
endogenous GLP-1 secretion in all groups and increased post-
prandial glucose, glucagon, and GE in T1D+ and T1D2 patients.
The insulinogenic index (the ratio of insulin to glucose) decreased
in T1D+ patients during blockade of endogenous GLP-1 receptor
action.
CONCLUSIONS—Type 1 diabetic patients have normal incretin
responses to meals. In type 1 diabetic patients, exogenous GLP-1
decreases peak postprandial glucose by 45% regardless of re-
sidual b-cell function. Endogenous GLP-1 regulates postprandial
glucose excursions by modulating glucagon levels, GE, and b-cell
responsiveness to glucose. Long-term effects of GLP-1 in type 1
diabetic patients should be investigated in future clinical trials.
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t time of diagnosis and during the ﬁrst year,
prevalence of residual b-cell function in patients
with type 1 diabetes is nearly 100% (1,2). After
alleviation of initial hyperglycemia with exoge-
nous insulin, patients enter a remission period with im-
proved b-cell function, where insulin treatment can be
paused in up to 20–30% of the patients without loss of
target glycemic control (3). Persistence of residual insulin
secretion is associated with reduced risk of ketosis (4),
lower HbA1c levels (5), lower insulin doses, less risk of
hypoglycemia, and reduced long-term complications (2,6).
However, after disease duration of 5–10 years, the preva-
lence of residual b-cell function has declined to about 15%
(2). Even though lack of insulin is considered to be the
most important factor for the hyperglycemia in type 1 di-
abetic patients, other metabolic disturbances may also
play a role: the glucagon response to carbohydrate and
protein ingestion has been shown to be abnormal (7) and
there is evidence that postprandial hyperglycemia is be-
cause of lack of insulin as well as inappropriately elevated
glucagon levels (8,9). The gut hormone, glucagon-like pep-
tide 1 (GLP-1), reduces glucagon levels, increases insulin
secretion (10), and inhibits gastric emptying rate (GE),
thereby reducing postprandial glucose excursions (11).
The insulinotropic and the glucagonostatic properties of
GLP-1 are glucose dependent (12), and exogenous GLP-1,
therefore, does not produce hypoglycemia. Several studies
have found lowering of fasting and postprandial glucose by
GLP-1 or GLP-1 agonists in type 1 diabetic patients with
(13–15) as well as without (16–19) residual b-cell function.
Some studies suggested that the glucose lowering effect
was because of the enhancement of insulin sensitivity (19),
whereas others concluded that delay of gastric emptying
(13,14) or reduction of glucagon levels (17) was the most
important mechanism. In animal studies, treatment with
GLP-1 or GLP-1 agonists has been shown to delay diabetes
development or reverse recent onset diabetes in NOD mice
(20), ascribed to an improved function of existing b-cells
rather than through increments in b-cell mass. However,
there is also evidence that GLP-1, in combination with
gastrin, increases b-cell mass and restores normoglycemia
in recent onset diabetic NOD mice (21) and that GLP-1
combined with gastrin is able to expand b-cell mass of
human islets implanted under the renal capsule of immu-
nodeﬁcient diabetic NOD mice (22). In freshly isolated
human islets, GLP-1 has been reported to inhibit b-cell
apoptosis (23). However, in C-peptide–positive subjects
with longstanding type 1 diabetes treated with exenatide
for 6 to 9 months with or without daclizumab, insulin dose
was signiﬁcantly reduced, primarily because of the reduction
of prandial insulin, but b-cell function was not improved
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ORIGINAL ARTICLE(15). Four weeks of treatment with vildagliptin (a DPP-4
inhibitor that increases endogenous GLP-1 levels) in 11
well-controlled type 1 diabetic patients with longstanding
disease decreased postmeal glucagon and glucose levels
(24), and in adolescents with minimal or no endogenous
insulin secretion treated with exenatide, postprandial glu-
cose excursions were reduced despite 20% reduction of
insulin dose (25). Therefore, GLP-1–based therapies have
potential for treatment of type 1 diabetes alone or—more
likely—in combination with insulin.
Because of controversies regarding secretion of incretin
hormones in type 1 diabetes (26,27), assessment of the
meal-related GLP-1 secretory responses in patients with
diabetes is of interest (28). We therefore studied incretin
secretion as well as the antidiabetic actions of both en-
dogenously secreted and exogenously infused GLP-1 dur-
ing a mixed meal in type 1 diabetic patients with and
without residual b-cell function.
RESEARCH DESIGN AND METHODS
Subjects. Sixteen type 1 diabetic Caucasian patients and eight healthy con-
trol subjects were studied. Eight patients had residual b-cell function (T1D+),
and eight were without (T1D2). All diabetic subjects were diagnosed between
8 and 40 years old; all were normal or underweight at diagnosis and were
treated with multiple daily insulin injections from time of diagnosis. None had
other diseases affecting glucose metabolism, overt diabetes complications, or
symptoms of autonomic nerve dysfunction. Control subjects were healthy, had
a normal oral glucose tolerance test, and no family history of diabetes.
Patients and control subjects were matched with respect to age, sex, and BMI.
T1D+ and T1D2 patients had similar HbA1c, age, and BMI, but T1D2 patients
had a longer duration of diabetes (10.6 6 2.2 vs. 3.2 6 0.7 years [mean 6 SEM;
P , 0.05]) and required more insulin (47.4 6 3.5 vs. 31.9 6 3.6 IE/day [mean 6
SEM, P , 0.05]). Subject characteristics are presented in Table 1. The protocol
was approved by the Ethical Committee for Region Hovedstaden and the
Danish Data Protection Agency and conducted according to the principles of
the Helsinki Declaration 2.
Glucagon test. To assess residual b-cell function, a glucagon stimulation test
(GST) was performed at blood glucose levels above 7 mmol/L. Fasting plasma
C-peptide concentrations were measured before and 6 min after intrave-
nous bolus-injection of 1 mg glucagon (29). Patients were classiﬁed as T1D+
when stimulated plasma C-peptide concentration was $200 pmol/L and T1D2
if below the detection limit of 0.1 ng/mL (;33 pmol/L) (See Table 1).
Experimental protocol. Patients were investigated after an overnight fast
(10 h). The night before, they injected normal dose of long acting insulin. An
individualdifferenceinfastingplasmaglucoseofnomorethan3mmol/Lbetween
study days was allowed. Cannulas were inserted in forearms: one for infusions
and one for blood sampling with arterialization of the venous blood using the
heated hand technique. After basal blood sampling, GLP-1 (1.2 pmol/kg/min),
saline, or the GLP-1 receptor antagonist exendin 9-39 (Ex9-39; 300 pmol/kg/min)
was infused for 3 h. This dose of Ex9-39 blocks 95% of the insulinotropic and
completely antagonizes the glucagonostatic effects of physiological levels of
GLP-1 (30). Infusions were randomized and single blinded. Thirty minutes
after infusion start (time zero), participants consumed a mixed meal of 2.036
KJ (;485 kcal: 23.6% protein, 15.2% fat, and 45.9% carbohydrates). One gram
of acetaminophen was added to the yogurt, which was part of the meal. The
whole meal was eaten within 20 min, and the yogurt was eaten within the ﬁrst
10 min. Before the meal, patients injected half-dose of their usual fast acting
insulin (Novorapid was injected at time zero, and Actrapid at time 215 min).
For each subject, insulin dose, injection site, as well as exact time until meal
completion were identical on the three study days. Blood samples for analysis
of plasma glucose, C-peptide, insulin, free fatty acids (FFA), triglycerides
(TG), glucagon, intact GIP, total GLP-1, and Ex9-39 were drawn at 245, 240,
235, 230 (infusion start), 220, 210, 0 (meal served), 10, 20 (meal ﬁnished),
30, 40, 50, 60, 75, 90, 105, 120, 150, and 180 min.
Analytical methods. Plasma glucose was analyzed bedside with an ABL800
blood gas analyzer (Radiometer, Copenhagen, Denmark). C-peptide responses
to the GST were analyzed with solid-phase two-site chemiluminiscent immu-
nometricassay(Immulite2000),withadetectionlimitof0.1ng/mL(;33pmol/L).
Plasma C-peptide during the meal test was measured by autoDELPHIA auto-
matic ﬂouroimmunoassay (Wallac, Turku, Finland), with a detection limit of
17 pmol/L. Blood was collected in chilled heparinized tubes and centrifuged
immediately, and plasma was held on ice and stored at 280°C until analyzed.
Blood samples for glucagon, total GLP-1, and intact GIP were sampled in tubes
containing EDTA and DPP-4 inhibitor (valpyr). The antiserum of glucagon
assay (code no. 4305) is directed against the C-terminus of glucagon and
reacts speciﬁcally with pancreatic glucagon (31). Unexpectedly, we observed
weak cross-reaction with Ex9-39 in concentrations above 10
27 mol/L. All glu-
cagon samples were therefore also measured with the LINCO assay (Milipore,
Billerica, MA), which did not cross-react with Ex9-39 at all (own results) but
had a poorer sensitivity. Total GLP-1 concentrations were measured using
antiserum no. 89390, reacting equally with intact GLP-1 (7–36) amide and its
primary N-terminally truncated metabolite GLP-1 (9–36) amide (32). Intact GIP
was measured using antiserum no. 98171, reacting with the N-terminus of GIP,
but not with the metabolite, GIP 3–42 (33). Detection limits and intra-assay
coefﬁcients were 1 and 2 pmol/L and less than 6% for GLP-1 and GIP, re-
spectively. Ex9-39 was measured in EDTA plasma using antibody 3145 ob-
tained from rabbits immunized with exendin 4. It shows 100% cross-reactivity
with Ex9-39 but ,0.01% cross-reactivity with GIP, glucagon, or GLP-1. Intra-
assay coefﬁcient of variation is ,6%, with a detection limit of 0.5 pmol/L.
Serum non-esteriﬁed FFA and TG were measured by oxidase colorimetric
methods (Wako Chemicals, Neuss, Germany; and products VITROS Chemis-
try, Ortho-Clinical Diagnostics, Buckinghamshire, U.K.). Acetaminophen was
analyzed by ﬂuorescence polarization immunoassay technology (Abbott Lab-
oratories, Abbot Park, IL).
Insulin secretion rates. For T1D+ patients and control subjects, prehepatic
insulin secretion rates (ISR) were calculated through deconvolution of pe-
ripheral C-peptide concentrations using two-compartment model of C-peptide
kinetics (34,35) and population-based C-peptide kinetics with adjustment for
metabolic parameters such as age, sex, and BMI (36). ISR is expressed in units
of picomoles 3 kilograms
21 3 minutes
21.
Insulinogenic index. Insulinogenic index was calculated as the ratio of in-
cremental integral ISR and plasma glucose from start of infusion (230 min)
until termination of the 3-h meal test (180 min), (ISR/PG210) during saline and
Ex9-39 infusion, respectively.
Statistical analyses and calculations. Data are presented as mean 6 SEM.
Baseline values are calculated as the mean of the four fasting values. In-
tegrated area under the plasma concentration curves (AUC) was calculated
using the trapezoidal rule, with subtraction of baseline values when
TABLE 1
Subject characteristics
T1D2 patients T1D+ patients Control subjects
Sex (male/female) 6/2 6/2 6/2
Age (years) 32.1 6 2.2 26.9 6 1.0 27.9 6 5.4
BMI (kg/m
2) 23.5 6 0.6 24.4 6 2.8 23.8 6 0.4
HbA1c (%) 6.93 6 0.20 6.35 6 0.20 5.10 6 0.10
Diabetes duration (years) 10.6 6 2.2* 3.2 6 0.7 —
ICA (positive/negative) 3/5 2/6 —
GAD-65 (positive/negative) 6/2 7/1 —
Insulin (IE/day) 47 6 3.5* 31.9 6 0.5 —
Meal insulin (IE) (study days) 3.80 6 0.84* 2.6 6 0.5 —
Stimulated C-peptide (pM) ,33* 456 6 221 —
Data are mean 6 SEM. Characteristics of type 1 diabetic patients without (2) and with (+) residual b-cell function and control subjects.
GAD-65, glutamic acid decarboxylase-65; ICA, islet cell antibody. *P , 0.05 vs. T1D+.
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using Student t test; paired within groups and unpaired between groups and
nonnormally distributed data using nonparametric tests. Three or more data-
sets were evaluated using one-way ANOVA between groups and repeated-
measurements ANOVA within groups. Differences resulting in P values # 0.05
were considered statistically signiﬁcant.
RESULTS
GIP. Data are presented in Fig. 1A–C and Table 2. With
saline, baseline intact GIP (iGIP) concentrations were 14–
18 pmol/L and did not differ within or between the three
groups on either study day, and peak plasma concen-
trations were 82 6 8, 67 6 7, and 85 6 8 pmol/L in the
T1D2, T1D+, and control subjects, respectively (P 5 0.2).
When compared with saline, plasma concentration of iGIP
was signiﬁcantly decreased in all three groups during GLP-1
infusion but did not change under Ex9-39 infusion (Table 2).
Total AUC0–180 min of iGIP during saline was 9.3 6 1.0,
7.5 6 0.4, and 10.2 6 0.9 nmol/L 3 min, in T1D2, T1D+, and
control subjects (P =0 . 0 8 ) .
GLP-1. Data are presented in Fig. 1D–F and Table 2. Mean
baseline concentrations of GLP-1 were 15–20 pmol/L and
did not differ within or between the three groups on the 3
study days. On the saline day, peak GLP-1 was 47 6 5, 44 6 6,
and 54 6 8 pmol/L (P = 0.5). Infusion of GLP-1 increased
mean plasma levels of GLP-1 to ;200 pmol/L in all groups,
and steady state plasma levels of GLP-1 were achieved
before the meal was served. With saline, total AUC0–180 min
of GLP-1 did not differ between groups (P = 0.5) (Table 2).
When compared with saline, Ex9-39 signiﬁcantly increased
secretion of GLP-1, but the GLP-1 response achieved
during Ex9-39 did not differ between groups (P =0 . 6 )
(Table 2).
Exendin 9-39. Data are presented in Fig. 2. On Ex9-39
days, plasma levels of Ex9-39 increased to 60 nmol/L in all
three groups before the meal was served, corresponding to
levels where insulinotropic effects of physiological GLP-1
levels was completely abolished (37). Ex9-39 levels con-
tinued to increase reaching plateau levels of 100–120 nmol/L
about 120 min after the meal was served. Total AUC0–180 min
of Ex9-39 did not differ between groups; 16.8 6 1.0, 17.3 6
2.5, and 19.7 6 1.3 nmol/L 3 min in T1D2, T1D+, and
control subjects, respectively (P = 0.5). There was no cor-
relation between Ex9-39 and glucagon concentrations.
Glucose. Data are presented in Fig. 3A–C and Table 3.
Within each group, baseline plasma glucose (PG) did not
differ between the 3 study days, but were higher in both
diabetic groups compared with control subjects. During
saline, peak PG were 6.9 6 0.2 mmol/L in control subjects
and 14.2 6 0.9 and 16.2 6 1.5 mmol/L in T1D+ and T1D2
patients, respectively, but with GLP-1 infusion, peak PG
decreased to 8.6 6 1.3 and 7.5 6 0.7 mmol/L in T1D2 and
T1D+ patients and to 5.8 6 0.2 mmol/L in the control
subjects (P , 0.01 vs. saline for all three groups). GLP-1
infusion decreased peak PG by 45.4 6 17.7% in the T1D2
patients and 45.1 6 16.2% in the T1D+ patients compared
with saline. Peak PGs in both diabetic groups were similar to
control subjects receiving saline (P = 0.3). GLP-1 also sig-
niﬁcantly decreased total and incremental AUC230 to 180 min
of glucose in all three groups, and in both groups of
patients, total AUC230 to 180 min did not signiﬁcantly differ
from control subjects receiving saline (Table 3). Ex9-39
signiﬁcantly increased total and incremental AUC230 to 180 min
in T1D+ patients, but not in T1D2 patients or control
subjects (Table 3). However, compared with saline, Ex9-39
signiﬁcantly increased total AUC02180 min from 2.53 6 0.23
to 2.90 6 0.21 (P , 0.05) and from 2.19 6 0.14 to 2.46 6
0.14 (P , 0.01) mol/L 3 min in T1D2 and T1D+ patients,
respectively, whereas no differences were found in con-
trol subjects.
Glucagon. Glucagon data measured by the sensitive
RIA (weak cross-reaction with Ex9-39) are presented in
FIG. 1. A–C: Intact GIP (pM). D–F: Total GLP-1 (pM) during infusion with GLP-1 (red symbols), saline (gray symbols), and Ex9-39 (blue symbols)
in T1D2 (■), T1D+ (●), and control subjects (▲) during a mixed meal test. Solid arrow: start of infusion; open arrow: meal start. T1D2:t y p e1
diabetic patients without residual b-cell function; T1D+: type 1 diabetic patients with residual b-cell function.
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measured by the LINCO assay (no cross-reaction with Ex9-39)
are presented in Supplementary Table 1 and Fig. 1. Mean
baseline glucagon was 5.2 6 1.5, 8.3 6 0.6, and 6.2 6 0.7
pmol/L (P = 0.3) in the T1D2, T1D+, and control subjects.
With saline, neither incremental nor total AUC230 to 180 min
differed between groups (P = 0.9 and P = 0.2, respectively;
Table 3). When compared with saline, GLP-1 infusion de-
creased total and incremental AUC230 to 180 min of glucagon
in all three groups (Table 3), mainly because of decre-
ments in postprandial levels since GLP-1 also decreased
total AUC0–180 min from 1.42 6 0.24 to 0.55 6 0.12 (P =
0.001), from 2.27 6 0.39 to 1.34 6 0.27 (P = 0.002), and
from 1.74 6 0.36 to 0.86 6 0.10 (P = 0.016) in T1D2, T1D+,
and control subjects, respectively. Ex9-39 signiﬁcantly in-
creased total and incremental AUC230 to 180 min of glucagon
in the patients with diabetes regardless of glucagon assay
used (Table 3 and Supplementary Data). The increase was
mainly due to increments in postprandial levels; total
AUC0–180 min increased to 3.38 6 0.26 (P , 0.001), 4.40 6
0.69 (P , 0.001), and 2.74 6 0.21 (P = 0.018) (vs. saline) in
T1D2, T1D+, and control subjects. The supplementary
glucagon data (without cross-reaction with Ex9-39) shows
that Ex9-39 signiﬁcantly increased total and incremental
AUC of glucagon in both groups of type 1 diabetic patients
and increased incremental AUC230 to 180 min in control sub-
jects.
C-peptide. C-peptide data are presented in Fig. 3G–I and
Table 3. None of the T1D2 patients displayed C-peptide
levels above 33 pmol/L. During GLP-1 infusion, total and
incremental AUC230 to 180 min of C-peptide decreased signiﬁ-
cantly in T1D+ patients (Table 3). However, fasting C-peptide
increased transiently with incremental AUC230 to 0 min of
0.60 6 0.24 (saline) vs. 4.39 6 2.02 (GLP-1) nM 3 min (P =
0.02). Ex9-39 decreased total and tended to decrease in-
cremental AUC230 to 180 min,o fC - p e p t i d e( P =0 . 0 5a n d
P = 0.06, respectively), and total AUC0–180 min also sig-
niﬁcantly decreased from 103.8 6 33.6 (saline) vs. 90.6 6
30 (Ex9-39) (P = 0.02).
In control subjects, C-peptide showed the same pattern as
in T1D+ patients; GLP-1 decreased total AUC230 to 180 min
(Table 3), but increased fasting incremental AUC230 to 0 min
of C-peptide from 20.61 6 1.13 (saline) to 7.68 6 2.7
(GLP-1) nM 3 min (P , 0.01). There were no signiﬁcant
differences in fasting or postprandial C-peptide responses
between Ex9-39 and saline, but C-peptide tended to be
lower during Ex9-39 (Table 3).
ISR. In T1D+ patients, Ex9-39 tended to decrease in-
cremental AUC230 to 180 min of ISR from 0.28 6 0.9 to
0.22 6 0.1 nmol 3 kg
21 (P = 0.06; vs. saline) but no dif-
ference was found in the control subjects (P = 0.5).
However, in T1D+ patients, the insulinogenic index, cal-
culated as the ratio of incremental integral ISR and PG
from 230 to 180 min (ISR/PG210), decreased with Ex9-39:
TABLE 2
Postprandial incretin responses related to infusion type
T1D2
patients
T1D+
patients
Control
subjects
P
between
groups
GIP
GLP-1 5.13 6 0.6** 4.13 6 0.45** 6.04 6 0.5** 0.07
Saline 9.28 6 1.0 7.48 6 0.4 10.20 6 0.9 0.08
Ex9-39 8.85 6 1.0 7.15 6 0.7 9.12 6 0.7 0.2
GLP-1
GLP-1 29.60 6 4.1** 30.30 6 2.0** 33.76 6 1.9** 0.5
Saline 5.20 6 0.5 5.32 6 0.6 6.16 6 0.6 0.5
Ex9-39 7.00 6 0.5** 7.56 6 0.9** 8.29 6 1.1* 0.6
Data are mean 6 SEM. Total integrated AUC (TAUC; 0–180 min) of
total GLP-1 and iGIP (nM 3 min) during infusion with GLP-1, saline,
or Ex9-39 in type 1 diabetic patients without (2) and with (+) re-
sidual b-cell function and control subjects. *P # 0.05 vs. saline; **P ,
0.01 vs. saline within the same group; no signiﬁcant differences were
found between groups at any infusion type.
FIG. 2. Plasma Ex9-39 (nM) on the day assigned to Ex9-39 infusion (blue symbols) in T1D2 (■), T1D+ (●) and control subjects (▲). Solid arrow:
start of infusion; open arrow: meal start. T1D2: type 1 diabetic patients without residual b-cell function; T1D+: type 1 diabetic patients with
residual b-cell function.
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21 3
min
21/mmol 3 L
21 (P , 0.01). In control subjects the
change in (ISR/PG210) was not signiﬁcant (P = 0.4). Time
courses of ISR for T1D+ and control subjects are shown in
Fig. 3J and K.
GE. With saline, time to peak of plasma acetaminophen was
60 6 8, 62 6 13, and 82 6 14 min (P = 0.5) and AUC0–180 min
was 7.91 6 0.51, 7.92 6 0.32, and 8.62 6 0.80 nmol/L 3 min
(P =0 . 6 )i nT 1 D 2, T1D+, and control subjects, respectively.
With GLP-1, AUC0–180 min decreased to 1.99 6 0.90,
FIG. 3. A–C: Plasma glucose (mM). D–F: Plasma glucagon (pM). G–I: Plasma C-peptide (pM). J and K: ISR (pmol 3 kg
21 3 min
21) during infusion
with GLP-1 (red symbols), saline (gray symbols), and Ex9-39 (blue symbols) in T1D2 (■), T1D+ (●), and control subjects (▲) during a mixed
meal test. Solid arrow: start of infusion; open arrow: meal start. T1D2: type 1 diabetic patients without residual b-cell function; T1D+: type 1
diabetic patients with residual b-cell function.
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0.01, and P , 0.05 vs. saline) in T1D2, T1D+, and control
subjects, respectively. Time-to-peak increased to 159 6
14, 140 6 17, and 150 6 15 min (P , 0.05 compared with
saline). Ex9-39 decreased time-to-peak by about 20 min in
all three groups, but the difference reached signiﬁcance
only in the T1D2 group. However, when the two diabetic
groups were considered together, Ex9-39 shifted AUC0–180 min
from 7.9 6 0.3 to 8.6 6 0.8 nmol/L 3 min (P = 0.046) and
time-to-peak from 61 6 7t o4 26 5 min (P = 0.02 compared
with saline).
Effect of endogenous and exogenous GLP-1 on plasma
lipids. Data are presented in Fig. 4A–F. Fasting TG con-
centrations tended to be higher in the healthy subjects
(1.1 6 0.2 mmol/L) than in T1D+ (0.7 6 0.09 mmol/L) and
T1D2 (0.6 6 0.08 mM) patients, on the saline day (P =0 . 0 8 ) .
Neither GLP-1 nor Ex9-39 infusions signiﬁcantly affected
TG concentrations. Fasting FFA did not differ within or
between groups (fasting FFA ;0.4–0.5 mmol/L) except for
T1D+ subjects on the day assigned to Ex9-39 where fasting
FFA levels were almost twice as high (;0.7 mmol/L). FFA
concentrations decreased in all groups after ingestion of the
meal regardless of infusion type.
DISCUSSION
We conclude that incretin responses to a mixed meal test
are similar between type 1 diabetic patients with as well as
without residual b-cell function and healthy subjects. This
is in contrast with results from Lugari et al. (26), who
reported absence of postprandial GLP-1 responses in type
1 diabetes, but in agreement with data from Vilsbøll et al.
(27), who found incretin responses in type 1 diabetic
patients equal to that of lean healthy controls. We have no
clear explanation for this discrepancy other than differ-
ences in methodology or subject characteristics (28). Our
study conﬁrms that chronic hyperglycemia in lean type 1
diabetic patients in otherwise good metabolic control does
not decrease L-cell secretory response to a mixed meal.
Blocking the effect of endogenous GLP-1 with Ex9-39 in-
creased postprandial GLP-1 consistent with earlier ﬁndings
in healthy subjects (38) and in type 2 diabetic patients (39).
This could theoretically be the result of 1) increases in GE
(with more nutrients reaching the intestine and the L-cells
[40]), 2) blockade of a negative feedback system between
the GLP-1 and the L-cell (41), 3) changes in plasma clear-
ance of GLP-1 (because the GLP-1 receptor [GLP-1R] is
expressed in tubular cells of the kidneys and might be
involved in the very high renal extraction of GLP-1 [42]),
and 4) cross-reactions with Ex9-39 in the GLP-1 assay as
previously described (37), but this was excluded in the
current study. During infusion of saline, GIP increased to
the same extent in the three groups but was clearly de-
creased during GLP-1 infusion, presumably because of
delayed GE.
GLP-1 infusion, despite a 50% dose-reduction of usual
fast-acting prandial insulin, effectively reduced post-
prandial glucose-excursions in T1D+ and T1D2 patients.
In T1D+ patients postprandial glucose decreased and be-
came indistinguishable from those of healthy subjects re-
ceiving saline, and in T1D2 patients, it remained at fasting
values. This clearly antidiabetic effect is in accordance
with a previous study (19), where GLP-1 infusion de-
creased the isoglycemic meal-related insulin requirement
by 50%, which was thought to be because of increased
glucose utilization as well as a decrease in glucagon re-
lease. However, another study did not ﬁnd evidence of an
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abetic patients (43). In yet another study of type 1 diabetic
patients with residual b-cell function who omitted their
prandial insulin, postprandial glucose elevations were
completely prevented without stimulation of endogenous
insulin, whereas glucagon and pancreatic polypeptide (PP)
were suppressed (13). Six to nine months of exenatide
treatment in patients with longstanding type 1 diabetes and
measurable C-peptide levels decreased preprandial insulin
by 30% but did not affect b-cell function or glucagon levels
(15). The patients’ C-peptide level in that study was rela-
tively small (mean stimulated of about 270 pmol/L). Our
T1D+ patients had stimulated C-peptide levels about twice
as high, which could explain the difference in effect of
GLP-1 treatment on glucose metabolism. However, we also
found a strong GLP-1–induced glucose lowering effect in
our T1D2 patients. The remaining b-cells in our T1D+
patients responded well to GLP-1 stimulation, as clearly
shown in the premeal period (where PG levels were still
above 6 mmol/L), and improved insulin secretion may have
contributed to the reduction of postprandial glucose
excursions. It is possible that the glucose lowering effect
observed here—regardless of residual insulin secretion—
is mainly caused by the combination of reduced glucagon
levels and inhibition of GE. The observation that DPP-4
inhibition reduces postprandial glucose excursions in type
1 diabetic patients through b-cell independent suppres-
sion of glucagon (24) but has no or little effect on GE (44),
supports a particular role for glucagon suppression. Block-
ing the effect of endogenous GLP-1 decreased postprandial
(0–180 min) C-peptide level in the T1D+ patients despite
slightly elevated PG values, suggesting that endogenously
secreted GLP-1 might affect b-cell responsiveness to glu-
cose. Accordingly, Ex9-39 signiﬁcantly decreased the
insulinogenic index (PG/ISR210) in the T1D+ patients and
increased postprandial glucagon levels most pronounced in
the patients with diabetes. Thus endogenous GLP-1 seems
to participate in the regulation of postprandial glucagon
secretion in type 1 diabetic patients and enhances the b-cell
responsiveness to glucose during a mixed meal. The ab-
sence of an effect of GLP-1R blockade on glucose excursions
and b-cell function in control subjects may be because of the
low glycemic index of the meal resulting in modest glucose
excursions and therefore reduced insulinotropic effects of
incretin hormones. Furthermore, because insulinotropic
effect of GIP is severely impaired in type 1 diabetes (45),
but explains about half of the incretin effect in healthy
humans (46), Ex9-39 (which only antagonizes GLP-1, but
does not affect insulinotropic action of GIP) might abolish
the incretin effect relatively more in the patients as observed.
As expected, GLP-1 strongly decreased GE in all groups
accompanied by a reduction of GIP secretion. Ex9-39 ac-
celerated GE in type 1 diabetic patients but did not sig-
niﬁcantly affect GE rate in control subjects. Using the
same antagonist but scintigraphy for detection of emptying
rates, Deane et al. (47) found accelerated GE in healthy
humans, inﬂuencing glucose absorption and postprandial
glycemia. Therefore, insufﬁcient statistical power may be
partly responsible for the insigniﬁcant effect observed
here. Furthermore, in healthy subjects and in type 1 di-
abetic patients, hyperglycemia decelerates GE, whereas
hypoglycemia increases it (48–51), and differences in glu-
cose levels by infusion type may therefore indirectly have
affected GE in our patients.
FIG. 4. A–C: FFA (mM). D–F: TG (mM) during infusion with GLP-1 (red symbols), saline (gray symbols), and Ex9-39 (blue symbols) in T1D2 (■),
T1D+ (●), and control subjects (▲) during a mixed meal test. Solid arrow: start of infusion; open arrow: meal start. T1D2: type 1 diabetic patients
without residual b-cell function; T1D+: type 1 diabetic patients with residual b-cell function.
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gardless of infusion type, but we have no explanation for
the elevated fasting FFA in the T1D+ patients on the
Ex9-39 day other than natural variation. It has been shown
that treatment with GLP-1 and DPP-4 inhibitors reduces
intestinal lipid production and absorption, preventing
postprandial rise in TG (52,53). In our study, TG was un-
affected by the meal as well as by infusion type, except for
a weak (nonsigniﬁcant) trend of lower postprandial values
during GLP-1 infusion in all groups. The tendency of lower
TG levels in the patients compared with control subjects is
probably the result of exogenous insulin (52). In a recent
study, GLP-1R signaling was found to be essential for the
control of postprandial lipoprotein biosynthesis and se-
cretion at least in rodents (54), but our results suggest that
this may not apply to humans.
Conclusions. We conclude that type 1 diabetic patients
have normal incretin responses to a mixed meal and that
infusion of GLP-1 at the rate we used decreases peak
postprandial glucose by approximately 45% in type 1 di-
abetic patients regardless of b-cell function. Endogenously
secreted GLP-1 plays a role in the regulation of postprandial
glucose excursions in type 1 diabetes by modulating glu-
cagon levels, GE rate, and b-cell responsiveness to glu-
cose. We suggest that long term effects of GLP-1–based
therapies should be investigated in future clinical trials of
type 1 diabetic patients with as well as without residual
b-cell function.
ACKNOWLEDGMENTS
No potential conﬂicts of interest relevant to this article
were reported.
U.K. researched data and wrote the manuscript. J.J.H.
and S.M. reviewed and edited the manuscript and contrib-
uted to discussion.
The authors are indebted to the patients for their
willingness to participate in this study. The authors also
appreciate the technical assistance of Alis Andersen, Jette
Nymann, and Sussi Polmann (Hvidovre University Hos-
pital, Copenhagen, Denmark) and of Lene Albak and
Soﬁe Pilgaard (Department of Biomedical Sciences, the
Panum Institute, University of Copenhagen, Denmark). The
authors are especially grateful to Professor Michael Nauck,
Diabeteszentrum, Bad Leuterberg im Harz, Germany, who
very kindly provided the authors with the GLP-1 used in
this study. The authors also thank Aage Vølund, Bagsværd,
Copenhagen, for calculations of ISR and comments to the
manuscript.
REFERENCES
1. Greenbaum CJ, Anderson AM, Dolan LM, et al.; SEARCH Study Group.
Preservation of b-cell function in autoantibody–positive youth with di-
abetes. Diabetes Care 2009;32:1839–1844
2. Madsbad S. Prevalence of residual B cell function and its metabolic con-
sequences in type 1 (insulin-dependent) diabetes. Diabetologia 1983;24:141–147
3. Martin S, Pawlowski B, Greulich B, Ziegler AG, Mandrup-Poulsen T,
Mahon J. Natural course of remission in IDDM during 1st yr after di-
agnosis. Diabetes Care 1992;15:66–74
4. Madsbad S, Alberti KG, Binder C, et al. Role of residual insulin secretion in
protecting against ketoacidosis in insulin-dependent diabetes. BMJ 1979;2:
1257–1259
5. Sjöberg S, Gunnarsson R, Gjötterberg M, Lefvert AK, Persson A, Ostman J.
Residual insulin production, glycaemic control and prevalence of micro-
vascular lesions and polyneuropathy in long-term type 1 (insulin-dependent)
diabetes mellitus. Diabetologia 1987;30:208–213
6. Fukuda M, Tanaka A, Tahara Y, et al. Correlation between minimal se-
cretory capacity of pancreatic b-cells and stability of diabetic control.
Diabetes 1988;37:81–88
7. Müller WA, Faloona GR, Aguilar-Parada E, Unger RH. Abnormal alpha-cell
function in diabetes. Response to carbohydrate and protein ingestion. N
Engl J Med 1970;283:109–115
8. Dinneen S, Alzaid A, Turk D, Rizza R. Failure of glucagon suppression
contributes to postprandial hyperglycaemia in IDDM. Diabetologia 1995;
38:337–343
9. Unger RH, Orci L. The essential role of glucagon in the pathogenesis of
diabetes mellitus. Lancet 1975;1:14–16
10. Kjems LL, Holst JJ, Vølund A, Madsbad S. The inﬂuence of GLP-1 on
glucose-stimulated insulin secretion: effects on b-cell sensitivity in type 2
and nondiabetic subjects. Diabetes 2003;52:380–386
11. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007;87:
1409–1439
12. Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide
1 on counterregulatory hormone responses, cognitive functions, and in-
sulin secretion during hyperinsulinemic, stepped hypoglycemic clamp
experiments in healthy volunteers. J Clin Endocrinol Metab 2002;87:1239–
1246
13. Dupre J, Behme MT, Hramiak IM, et al. Glucagon-like peptide I reduces
postprandial glycemic excursions in IDDM. Diabetes 1995;44:626–630
14. Dupré J, Behme MT, Hramiak IM, McDonald TJ. Subcutaneous glucagon-
like peptide I combined with insulin normalizes postcibal glycemic ex-
cursions in IDDM. Diabetes Care 1997;20:381–384
15. Rother KI, Spain LM, Wesley RA, et al. Effects of exenatide alone and in
combination with daclizumab on b-cell function in long-standing type 1
diabetes. Diabetes Care 2009;32:2251–2257
16. Behme MT, Dupré J, McDonald TJ. Glucagon-like peptide 1 improved
glycemic control in type 1 diabetes. BMC Endocr Disord 2003;3:3
17. Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA. Glu-
cagonostatic actions and reduction of fasting hyperglycemia by exogenous
glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes
Care 1996;19:580–586
18. Dupré J, Behme MT, McDonald TJ. Exendin-4 normalized postcibal glycemic
excursions in type 1 diabetes. J Clin Endocrinol Metab 2004;89:3469–3473
19. Gutniak M, Orskov C, Holst JJ, Ahrén B, Efendic S. Antidiabetogenic effect
of glucagon-like peptide-1 (7-36)amide in normal subjects and patients
with diabetes mellitus. N Engl J Med 1992;326:1316–1322
20. Kielgast U, Holst JJ, Madsbad S. Treatment of type 1 diabetic patients with
glucagon-like peptide-1 (GLP-1) and GLP-1R agonists. Curr Diabetes Rev
2009;5:266–275
21. Suarez-Pinzon WL, Power RF, Yan Y, Wasserfall C, Atkinson M, Rabinovitch
A. Combination therapy with glucagon-like peptide-1 and gastrin restores
normoglycemia in diabetic NOD mice. Diabetes 2008;57:3281–3288
22. Suarez-Pinzon WL, Lakey JR, Rabinovitch A. Combination therapy with
glucagon-like peptide-1 and gastrin induces beta-cell neogenesis from
pancreatic duct cells in human islets transplanted in immunodeﬁcient di-
abetic mice. Cell Transplant 2008;17:631–640
23. Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell
apoptosis and improves glucose responsiveness of freshly isolated human
islets. Endocrinology 2003;144:5149–5158
24. Foley JE, Ligueros-Saylan M, He YL, et al. Effect of vildagliptin on gluca-
gon concentration during meals in patients with type 1 diabetes. Horm
Metab Res 2008;40:727–730
25. Raman VS, Mason KJ, Rodriguez LM, et al. The role of adjunctive exena-
tide therapy in pediatric type 1 diabetes. Diabetes Care 2010;33:1294–1296
26. Lugari R, Dell’Anna C, Ugolotti D, et al. Effect of nutrient ingestion on
glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2
diabetes. Horm Metab Res 2000;32:424–428
27. Vilsbøll T, Krarup T, Sonne J, et al. Incretin secretion in relation to meal
size and body weight in healthy subjects and people with type 1 and type 2
diabetes mellitus. J Clin Endocrinol Metab 2003;88:2706–2713
28. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-
like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Dia-
betologia 2011;54:10–18
29. Greenbaum CJ, Mandrup-Poulsen T, McGee PF, et al.; Type 1 Diabetes
Trial Net Research Group; European C-Peptide Trial Study Group. Mixed-
meal tolerance test versus glucagon stimulation test for the assessment of
b-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 2008;
31:1966–1971
30. Schirra J, Sturm K, Leicht P, Arnold R, Göke B, Katschinski M. Exendin(9-
39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in hu-
mans. J Clin Invest 1998;101:1421–1430
31. Orskov C, Jeppesen J, Madsbad S, Holst JJ. Proglucagon products in
plasma of noninsulin-dependent diabetics and nondiabetic controls in the
fasting state and after oral glucose and intravenous arginine. J Clin Invest
1991;87:415–423
EFFECT OF GLP-1 IN TYPE 1 DIABETIC PATIENTS
1606 DIABETES, VOL. 60, MAY 2011 diabetes.diabetesjournals.org32. Orskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma
concentrations of amidated and glycine-extended glucagon-like peptide I
in humans. Diabetes 1994;43:535–539
33. Deacon CF, Nauck MA, Meier J, Hücking K, Holst JJ. Degradation of
endogenous and exogenous gastric inhibitory polypeptide in healthy and
in type 2 diabetic subjects as revealed using a new assay for the intact
peptide. J Clin Endocrinol Metab 2000;85:3575–3581
34. Hovorka R, Soons PA, Young MA. ISEC: a program to calculate insulin
secretion. Comput Methods Programs Biomed 1996;50:253–264
35. Hovorka R, Koukkou E, Southerden D, Powrie JK, Young MA. Measuring
pre-hepatic insulin secretion using a population model of C-peptide kinetics:
accuracy and required sampling schedule. Diabetologia 1998;41:548–554
36. Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin se-
cretion rates from C-peptide levels. Comparison of individual and standard
kinetic parameters for C-peptide clearance. Diabetes 1992;41:368–377
37. Edwards CM, Todd JF, Mahmoudi M, et al. Glucagon-like peptide 1 has
a physiological role in the control of postprandial glucose in humans:
studies with the antagonist exendin 9-39. Diabetes 1999;48:86–93
38. Schirra J, Nicolaus M, Roggel R, et al. Endogenous glucagon-like peptide 1
controls endocrine pancreatic secretion and antro-pyloro-duodenal mo-
tility in humans. Gut 2006;55:243–251
39. Salehi M, Aulinger B, Prigeon RL, D’Alessio DA. Effect of endogenous GLP-1
on insulin secretion in type 2 diabetes. Diabetes 2010;59:1330–1337
40. Miholic J, Orskov C, Holst JJ, Kotzerke J, Meyer HJ. Emptying of the
gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypogly-
cemia after total gastrectomy. Dig Dis Sci 1991;36:1361–1370
41. Hansen L, Hartmann B, Bisgaard T, Mineo H, Jørgensen PN, Holst JJ.
Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from
isolated perfused porcine ileum. Am J Physiol Endocrinol Metab 2000;278:
E1010–E1018
42. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ. Glucagon-like peptide
1 undergoes differential tissue-speciﬁc metabolism in the anesthetized pig.
Am J Physiol 1996;271:E458–E464
43. Meneilly GS, McIntosh CH, Pederson RA, et al. Effect of glucagon-like
peptide 1 (7-36 amide) on insulin-mediated glucose uptake in patients with
type 1 diabetes. Diabetes Care 2003;26:837–842
44. Vella A, Bock G, Giesler PD, et al. Effects of dipeptidyl peptidase-4 in-
hibition on gastrointestinal function, meal appearance, and glucose me-
tabolism in type 2 diabetes. Diabetes 2007;56:1475–1480
45. Vilsbøll T, Knop FK, Krarup T, et al. The pathophysiology of diabetes in-
volves a defective ampliﬁcation of the late-phase insulin response to glucose
by glucose-dependent insulinotropic polypeptide-regardless of etiology and
phenotype. J Clin Endocrinol Metab 2003;88:4897–4903
46. Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Both GLP-1 and GIP are in-
sulinotropic at basal and postprandial glucose levels and contribute nearly
equally to the incretin effect of a meal in healthy subjects. Regul Pept 2003;
114:115–121
47. Deane AM, Nguyen NQ, Stevens JE, et al. Endogenous glucagon-like
peptide-1 slows gastric emptying in healthy subjects, attenuating post-
prandial glycemia. J Clin Endocrinol Metab 2010;95:215–221
48. Russo A, Stevens JE, Chen R, et al. Insulin-induced hypoglycemia accel-
erates gastric emptying of solids and liquids in long-standing type 1 di-
abetes. J Clin Endocrinol Metab 2005;90:4489–4495
49. Schvarcz E, Palmér M, Aman J, Lindkvist B, Beckman KW. Hypoglycaemia
increases the gastric emptying rate in patients with type 1 diabetes mel-
litus. Diabet Med 1993;10:660–663
50. Schvarcz E, Palmér M, Aman J, Berne C. Hypoglycemia increases the
gastric emptying rate in healthy subjects. Diabetes Care 1995;18:674–676
51. Schvarcz E, Palmér M, Aman J, Horowitz M, Stridsberg M, Berne C.
Physiological hyperglycemia slows gastric emptying in normal subjects
and patients with insulin-dependent diabetes mellitus. Gastroenterology
1997;113:60–66
52. Bunck MC, Diamant M, Cornér A, et al. One-year treatment with exenatide
improves b-cell function, compared with insulin glargine, in metformin-
treated type 2 diabetic patients: a randomized, controlled trial. Diabetes
Care 2009;32:762–768
53. Matikainen N, Mänttäri S, Schweizer A, et al. Vildagliptin therapy reduces
postprandial intestinal triglyceride-rich lipoprotein particles in patients
with type 2 diabetes. Diabetologia 2006;49:2049–2057
54. Hsieh J, Longuet C, Baker CL, et al. The glucagon-like peptide 1 receptor is
essential for postprandial lipoprotein synthesis and secretion in hamsters
and mice. Diabetologia 2010;53:552–561
U. KIELGAST, J.J. HOLST, AND S. MADSBAD
diabetes.diabetesjournals.org DIABETES, VOL. 60, MAY 2011 1607